EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

De-risking seizure liability: integrating adverse outcome pathways (AOPs), new approach methodologies (NAMs), and in silico approaches while highlighting knowledge gaps

Mamta Behl iD, Agnes Karmaus iD, Mohan Rao, Thomas Lane, Joshua Harris, Clifford Sachs, Alexandre Borrel iD, Oluwakemi Oyetade, Aswani Unnikrishnan iD, Jonathan Hamm, Helena T Hogberg iD

Toxicological Sciences · 01.10.2025 · 207 (2) · 306-319

DOI: 10.1093/toxsci/kfaf109 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Toxicological Sciences, online erschienen am 25.07.2025. Verfasst von Mamta Behl und 10 weiteren Autor:innen. Beteiligte Einrichtung: Neurocrine Biosciences Inc., San Diego, CA 92130, United States. Hauptthemen laut MEDLINE: Seizures, Adverse Outcome Pathways, Computer Simulation. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIEHS NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Animal studies are commonly used in drug development and in chemical and environmental toxicology to predict human toxicity, but their reliability, particularly in the central nervous system (CNS), is limited. For example, animal models often fail to predict drug-induced seizures, leading to unforeseen convulsions in clinical trials. Evaluating environmental compounds, such as pesticides, also poses challenges due to time and resource constraints, resulting in compounds remaining untested. To address these limitations, a government-industry collaboration identified 27 biological target families linked to seizure mechanisms by combining key events from adverse outcome pathways (AOPs) with drug discovery data. Over a hundred in vitro assay endpoints were identified, covering 26 of the target families, including neurotransmitter receptors, transporters, and voltage-gated calcium channels. A review of reference compounds identified 196 seizure-inducing and 34 seizure-negative chemicals, with 80% being tested in the in vitro assays. However, some target familes were more data-poor than others, highlighting significant data gaps. This proof-of-concept study demonstrates how mechanistic seizure liability can be assessed using an AOP framework and in vitro data. It underscores the need for expanded screening panels to include additional seizure-relevant targets. By integrating mechanistic insights into early drug development and environmental risk assessment, this approach enhances compound prioritization, complements animal studies, and optimizes resource use. Ultimately, this strategy refines CNS safety evaluation in drug development, improves public health protection to neurotoxicants, and bridges knowledge gaps.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SeizuresAdverse Outcome PathwaysComputer SimulationHumansAnimalsRisk Assessment

Stichwörter der Autor:innen

adverse outcome pathway (AOP)drug developmentenvironmental exposurein siliconew approach methodologies (NAMs)seizure

Autor:innen und Institutionen

  • Neurocrine Biosciences Inc., San Diego, CA 92130, United States.
  • Inotiv, Research Triangle Park, NC 27560, United States.
  • Collaborations Pharmaceutical Inc., Raleigh, NC 27606, United States.
  • NICEATM, DTT, NIEHS, NIH, Research Triangle Park, NC 27560, United States.

ORCID-Profile: Mamta Behl, Agnes Karmaus, Alexandre Borrel, Aswani Unnikrishnan, Helena T Hogberg

Förderung

  • NIGMS NIH HHS
  • NIEHS NIH HHS
  • NIH HHS
  • National Institue of Environmental Health Sciences
  • National Institute of Health
  • National Institute of Environmental Health Sciences
  • National Institutes of Health
  • National Institute of General Medical Sciences

Zitieren

APA

Behl, M., Karmaus, A., Rao, M., Lane, T., Harris, J., Sachs, C., Borrel, A., Oyetade, O., Unnikrishnan, A., Hamm, J., & Hogberg, H. T. (2025). De-risking seizure liability: integrating adverse outcome pathways (AOPs), new approach methodologies (NAMs), and in silico approaches while highlighting knowledge gaps. Toxicological Sciences, 207(2), 306-319. https://doi.org/10.1093/toxsci/kfaf109

Vancouver

Behl M, Karmaus A, Rao M, Lane T, Harris J, Sachs C, et al. De-risking seizure liability: integrating adverse outcome pathways (AOPs), new approach methodologies (NAMs), and in silico approaches while highlighting knowledge gaps. Toxicological Sciences. 2025;207(2):306-319. doi:10.1093/toxsci/kfaf109

BibTeX
@article{Behl2025,
  author = {Behl, Mamta and Karmaus, Agnes and Rao, Mohan and Lane, Thomas and Harris, Joshua and Sachs, Clifford and Borrel, Alexandre and Oyetade, Oluwakemi and Unnikrishnan, Aswani and Hamm, Jonathan and Hogberg, Helena T},
  title = {De-risking seizure liability: integrating adverse outcome pathways (AOPs), new approach methodologies (NAMs), and in silico approaches while highlighting knowledge gaps},
  journal = {Toxicological Sciences},
  year = {2025},
  volume = {207},
  number = {2},
  pages = {306--319},
  doi = {10.1093/toxsci/kfaf109}
}
Kostenlos starten →